Galectin Therapeutics Inc.

GALT

US3632252025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.29 ^USD	-2.66%		-3.24%	+98.19%

Mar. 29	Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	CI
Mar. 29	Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Galectin Therapeutics Inc.(NasdaqCM:GALT) dropped from Russell 3000E Growth Index

June 25, 2021 at 12:00 am EDT

Latest news about Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	Mar. 29	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	23-10-03	MT
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	23-10-03	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures Firmer Despite More China Stress	23-08-14	DJ
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Galectin Therapeutics Files $100 Million Mixed Shelf	23-04-17	MT
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stocks Seen -2-	23-03-30	DJ
Galectin Therapeutics Cleared by DSMB to Continue Belapectin Study in Patients with Liver Cirrhosis Caused by NASH	23-03-16	MT
Galectin Therapeutics Inc. Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	23-03-16	CI
Galectin Therapeutics Inc. Provides Final Randomization Status of Navigate, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	23-03-02	CI
Galectin Therapeutics Inc. Announces the End of Enrollment of Navigate, Its Seamless, Adaptive Phase 2B/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	23-01-05	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Neck Cancer Treatment With US FDA	22-10-12	MT
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer	22-10-12	CI
Galectin Therapeutics Files FDA Application for Belapectin	22-10-12	DJ
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE	22-10-06	CI
Galectin Therapeutics Inc.(NasdaqCM:GALT) dropped from S&P Global BMI Index	22-09-19	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI

Chart Galectin Therapeutics Inc.

Duration

Period

More charts

Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.38 USD

Average target price

11 USD

Spread / Average Target

+225.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GALECTIN THERAPEUTICS INC.	+98.19%	209M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research